These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38262811)

  • 1. What would have happened anyway? Population data source considerations when estimating background incident rates of adverse events following immunisation to inform vaccine safety.
    Clothier HJ; Shetty AN; Mesfin Y; Mackie M; Pearce C; Buttery JP
    Vaccine; 2024 Feb; 42(5):1108-1115. PubMed ID: 38262811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Background incidence rates of selected adverse events of special interest (AESI) to monitor the safety of COVID-19 vaccines.
    Pillsbury A; Phillips A; Deng L; Quinn H; Macartney K; Gidding H
    Vaccine; 2023 May; 41(22):3422-3428. PubMed ID: 37088604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of 'SAEFVIC', A Pharmacovigilance Surveillance Scheme for the Spontaneous Reporting of Adverse Events Following Immunisation in Victoria, Australia.
    Clothier HJ; Crawford NW; Russell M; Kelly H; Buttery JP
    Drug Saf; 2017 Jun; 40(6):483-495. PubMed ID: 28342074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and feasibility of SMS m-Health for the detection of adverse events following immunisation (AEFIs) in resource-limited setting-The Zimbabwe stimulated telephone assisted rapid safety surveillance (Zm-STARSS) randomised control trial.
    Nyambayo PPM; Gold MS; Mehta UC; Clarke S; Manyevere R; Chirinda L; Zifamba EN; Nyamandi T
    Vaccine; 2023 Oct; 41(45):6700-6709. PubMed ID: 37805357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine safety in Australia during the COVID-19 pandemic: Lessons learned on the frontline.
    Laemmle-Ruff I; Lewis G; Clothier HJ; Dimaguila GL; Wolthuizen M; Buttery J; Crawford NW
    Front Public Health; 2022; 10():1053637. PubMed ID: 36408022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Background rates of adverse events of special interest for COVID-19 vaccines: A multinational Global Vaccine Data Network (GVDN) analysis.
    Phillips A; Jiang Y; Walsh D; Andrews N; Artama M; Clothier H; Cullen L; Deng L; Escolano S; Gentile A; Gidding G; Giglio N; Junker T; Huang W; Janjua N; Kwong J; Li J; Nasreen S; Naus M; Naveed Z; Pillsbury A; Stowe J; Vo T; Buttery J; Petousis-Harris H; Black S; Hviid A
    Vaccine; 2023 Oct; 41(42):6227-6238. PubMed ID: 37673715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-vaccination healthcare attendance rate as a proxy measure for syndromic surveillance of adverse events following immunisation.
    Mesfin YM; Cheng AC; Enticott J; Lawrie J; Buttery J
    Aust N Z J Public Health; 2021 Apr; 45(2):101-107. PubMed ID: 33617131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study.
    Kang W; Shami JJP; Yan VKC; Ye X; Blais JE; Li X; Lee VHF; Chui CSL; Lai FTT; Wan EYF; Wong CKH; Wong ICK; Chan EW
    J Hematol Oncol; 2022 May; 15(1):66. PubMed ID: 35590336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019-2020.
    Moll K; Lufkin B; Fingar KR; Ke Zhou C; Tworkoski E; Shi C; Hobbi S; Hu M; Sheng M; McCarty J; Shangguan S; Burrell T; Chillarige Y; Beers J; Saunders-Hastings P; Muthuri S; Edwards K; Black S; Kelman J; Reich C; Amend KL; Djibo DA; Beachler D; Ogilvie RP; Secora A; McMahill-Walraven CN; Seeger JD; Lloyd P; Thompson D; Dimova R; MaCurdy T; Obidi J; Anderson S; Forshee R; Wong HL; Shoaibi A
    Vaccine; 2023 Jan; 41(2):333-353. PubMed ID: 36404170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surveillance of adverse events following immunisation: Australia 2002 to 2003.
    Lawrence G; Boyd I; McIntyre P; Isaacs D
    Commun Dis Intell Q Rep; 2004; 28(3):324-38. PubMed ID: 15574056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse Events Following Immunization- The Known Unknowns and Black Box : Based on 10th Dr. I. C. Verma Excellence Award for Young Pediatricians Delivered as Oration on 9th Oct. 2022.
    Das MK
    Indian J Pediatr; 2023 Aug; 90(8):817-825. PubMed ID: 37233889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surveillance of adverse events following immunisation: Australia, 2000-2002.
    Lawrence G; Menzies R; Burgess M; McIntyre P; Wood N; Boyd I; Purcell P; Isaacs D
    Commun Dis Intell Q Rep; 2003; 27(3):307-23. PubMed ID: 14510057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety monitoring of a new pentavalent vaccine in the expanded programme on immunisation in Ghana.
    Dodoo AN; Renner L; van Grootheest AC; Labadie J; Antwi-Agyei KO; Hayibor S; Addison J; Pappoe V; Appiah-Danquah A
    Drug Saf; 2007; 30(4):347-56. PubMed ID: 17408311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Annual report: Surveillance of adverse events following immunisation in Australia, 2005.
    Lawrence G; Boyd I; McIntyre P; Isaacs D
    Commun Dis Intell Q Rep; 2006; 30(3):319-33. PubMed ID: 17120485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expected Rates of Select Adverse Events After Immunization for Coronavirus Disease 2019 Vaccine Safety Monitoring.
    Abara WE; Gee J; Delorey M; Tun Y; Mu Y; Shay DK; Shimabukuro T
    J Infect Dis; 2022 May; 225(9):1569-1574. PubMed ID: 34958099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deaths reported to national surveillance for adverse events following immunization in China, 2010-2015.
    Wu W; Liu D; Nuorti JP; Li K; Xu D; Ye J; Zheng J; Cao L; Wang H
    Vaccine; 2019 Feb; 37(9):1182-1187. PubMed ID: 30709723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Active SMS-based surveillance of adverse events following immunisation with influenza and pertussis-containing vaccines in Australian pregnant women using AusVaxSafety.
    Glover C; Crawford N; Leeb A; Wood N; Macartney K
    Vaccine; 2020 Jun; 38(31):4892-4900. PubMed ID: 32499067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the role of human variation in vaccine adverse events: the Clinical Immunization Safety Assessment Network.
    LaRussa PS; Edwards KM; Dekker CL; Klein NP; Halsey NA; Marchant C; Baxter R; Engler RJ; Kissner J; Slade BA
    Pediatrics; 2011 May; 127 Suppl 1():S65-73. PubMed ID: 21502239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 vaccine safety in Scotland - background rates of adverse events of special interest.
    Cullen LA; Grange Z; Antal K; Waugh L; Alsina MS; Gibbons CL; MacDonald LE; Robertson C; Cameron JC; Stockton D; O'Leary MC
    Public Health; 2023 Nov; 224():1-7. PubMed ID: 37688806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active surveillance of adverse events following childhood immunization in Singapore.
    Thoon KC; Soh SB; Liew WK; Gunachandran A; Tan NW; Chong CY; Yung CF
    Vaccine; 2014 Sep; 32(39):5000-5. PubMed ID: 25045811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.